Mannitol Aguettant (Mannitol)

Mannitol increases the osmolarity of the extracellular fluid after intravenous administration. This osmotic gradient pulls water from intracellular spaces and edematous tissues into the bloodstream, promoting diuresis and reducing fluid accumulation in the brain, eye, and kidneys, which lowers pressure in those compartments.

The dosage of Mannitol Aguettant is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and response to therapy. Healthcare professionals calculate the appropriate infusion rate and total volume to achieve the desired therapeutic effect while monitoring safety parameters.

Mannitol’s safety in pregnancy and lactation has not been definitively established. It should only be used when the potential benefits to the mother outweigh any possible risks to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mannitol is a widely used osmotic diuretic that rapidly increases plasma osmolarity, whereas alternatives such as hypertonic saline may have a longer duration of action but different electrolyte effects. Choice of agent depends on the clinical scenario, desired speed of pressure reduction, and patient‑specific factors like renal function.

Mannitol Aguettant should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Ensure the container is tightly sealed and avoid exposure to extreme temperatures or direct sunlight to maintain product stability.

Mannitol Aguettant is given as an intravenous infusion. The solution is typically diluted with compatible IV fluids and administered over a controlled period, allowing clinicians to adjust the infusion rate based on the patient’s hemodynamic status and therapeutic response.

Serious risks include pulmonary edema, severe electrolyte disturbances (especially hyponatremia or hypernatremia), acute kidney injury, and rare anaphylactic reactions. Continuous monitoring of fluid balance, renal function, and vital signs is essential to detect and manage these complications promptly.

Mannitol is contraindicated in patients with known hypersensitivity to mannitol, severe dehydration, active intracranial hemorrhage where increased osmolarity could worsen bleeding, and in those with uncontrolled heart failure or pulmonary edema. Clinicians must assess each patient’s medical history before initiating therapy.